Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhNGF for HIV-Associated Sensory Neuropathy
NCT00000842Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nerve growth factor in Sensory neuropathy (SN) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Gracely Pain Scale at 18 weeks. Status: completed.
02
Drugs
Nerve growth factor
03
Conditions
Sensory neuropathy (SN)
Beyond the preview
Go deeper on NCT00000842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000842.